高出血风险患者可降解聚合物支架与耐久聚合物支架的随机对照试验
Bioflow-DAPT研究为国际多中心随机开放标签试验,纳入1948例高出血风险PCI患者,比较可降解聚合物西罗莫司洗脱支架与耐久聚合物佐他莫司洗脱支架在1个月双联抗血小板治疗后的安全性和有效性。1年时主要终点(心源性死亡、心肌梗死或支架血栓复合终点)发生率分别为3.6%和3.4%,可降解聚合物支架不劣于耐久聚合物支架(非劣效P<0.0001)。
要点
- 高出血风险患者PCI后1个月DAPT,可降解聚合物西罗莫司支架不劣于耐久聚合物佐他莫司支架。
- 1年主要终点事件率:可降解聚合物组3.6%,耐久聚合物组3.4%,风险差0.2个百分点。
- 非劣效性成立:单侧95%CI上限1.8,单侧97.5%CI上限2.1,均低于预设界值4.1%。
核心结论
- 在高出血风险并接受1个月DAPT的PCI患者中,可降解聚合物西罗莫司洗脱支架在1年心源性死亡、心肌梗死或支架血栓复合终点上不劣于耐久聚合物佐他莫司洗脱支架。
研究设计与样本
- Bioflow-DAPT研究为国际、随机、开放标签试验,于2020年2月24日至2021年9月20日在18个国家52个介入心脏病学中心开展。
- 共1948例因急性或慢性冠脉综合征接受PCI且符合至少1项高出血风险标准患者,1:1随机接受可降解聚合物西罗莫司支架(969例)或耐久聚合物缓释佐他莫司支架(979例)。
- 术后接受1个月双联抗血小板治疗,之后单一抗血小板治疗。
- 主要终点为1年心源性死亡、心肌梗死或支架血栓复合终点,按非劣效设计,绝对界值4.1%,单侧5%α。
主要发现
- 1年主要终点在可降解聚合物西罗莫司支架组发生33/969例(3.6%),耐久聚合物佐他莫司支架组发生32/979例(3.4%)。
- 风险差0.2个百分点,单侧95%CI上限1.8,单侧97.5%CI上限2.1。
- 非劣效性检验P<0.0001(两种检验均成立)。
关键数值与推荐
- 非劣效绝对界值为4.1%,单侧5%α。
- 主要终点1年事件率:可降解聚合物组3.6%,耐久聚合物组3.4%,风险差0.2个百分点。
- 单侧95%CI上限1.8,单侧97.5%CI上限2.1,均低于4.1%界值。
临床怎么用
- 对于高出血风险PCI患者,若计划1个月DAPT后转为单药抗血小板,可考虑选用可降解聚合物西罗莫司洗脱支架。
- 耐久聚合物佐他莫司洗脱支架在该人群同样表现良好,支架选择可结合临床具体情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Limited information is available on the comparative efficacy and safety of different stent platforms in patients at high bleeding risk undergoing an abbreviated dual antiplatelet therapy duration after percutaneous coronary intervention (PCI). The aim of this study was to compare the safety and effectiveness of the biodegradable-polymer sirolimus-eluting stent with the durable-polymer zotarolimus-eluting stent in patients at high bleeding risk receiving 1 month of dual antiplatelet therapy after PCI. METHODS: The Bioflow-DAPT Study is an international, randomized, open-label trial conducted at 52 interventional cardiology hospitals in 18 countries from February 24, 2020, through September 20, 2021. Patients with a clinical indication to PCI because of acute or chronic coronary syndrome who fulfilled 1 or more criteria for high bleeding risk were eligible for enrollment. Patients were randomized to receive either biodegradable-polymer sirolimus-eluting stents or durable-polymer, slow-release zotarolimus-eluting stents after successful lesion preparation, followed by 1 month of dual antiplatelet therapy and thereafter single antiplatelet therapy. The primary outcome was the composite of death from cardiac causes, myocardial infarction, or stent thrombosis at 1 year, and was powered for noninferiority, with an absolute margin of 4.1% at 1-sided 5% alpha. RESULTS: A total of 1948 patients at high bleeding risk were randomly assigned (1:1) to receive biodegradable-polymer sirolimus-eluting stents (969 patients) or durable-polymer zotarolimus-eluting stents (979 patients). At 1 year, the primary outcome was observed in 33 of 969 patients (3.6%) in the biodegradable-polymer sirolimus-eluting stent group and in 32 of 979 patients (3.4%) in the durable-polymer zotarolimus-eluting stent group (risk difference, 0.2 percentage points; upper boundary of the 1-sided 95% CI, 1.8; upper boundary of the 1-sided 97.5% CI, 2.1; P<0.0001 for noninferiority for both tests). CONCLUSIONS: Among patients at high risk for bleeding who received 1 month of dual antiplatelet therapy after PCI, the use of biodegradable-polymer sirolimus-eluting stents was noninferior to the use of durable-polymer zotarolimus-eluting stents with regard to the composite of death from cardiac causes, myocardial infarction, or stent thrombosis. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT04137510.
引用
- Valgimigli M, Wlodarczak A, Tölg R, et al. Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial. Circulation. 2023. PMID: 37624364. doi:10.1161/CIRCULATIONAHA.123.065448
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。